Gritstone Oncology Inc. Stock News

Gritstone bio results from the phase 1/2 study, using SLATE vaccines in treating patients with KRAS mutant MSS-CRC and NSCLC, were positive with a 39% molecular response observed. Molecular response a

EMERYVILLE, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today annou

Red Hot Biotech Penny Stocks To Watch Right Now The post Why The Stock Market Is Down Today & 4 Penny Stocks To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.c

Red Hot Biotech Penny Stocks To Watch Right Now The post Why The Stock Market Is Down Today & 4 Penny Stocks To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.c

EMERYVILLE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today annou

EMERYVILLE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced

Gritstone bio Inc (NASDAQ: GRTS) has insufficient cash either to reach de-risking catalysts for its lead oncology program, GRANITE, or to support the clinical development of its second program, SLATE,

Upgrades William Blair upgraded the previous rating for Foot Locker Inc (NYSE:FL) from Sell to Hold. For the second quarter, Foot Locker had an EPS of $1.10, compared to year-ago quarter EPS of $2.21.

EMERYVILLE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announ

-- Paper reports that Gritstone’s tumor-specific, neoantigen vaccination approach drives priming and boosting of tumor-specific T cells, including cytotoxic CD8+ T cells -- -- T cells linked to mole

-- Expert in virology, immunology and vaccine development’s appointment effective August 12 -- -- Expert in virology, immunology and vaccine development’s appointment effective August 12 --

Gritstone bio Inc. (NASDAQ:GRTS ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants George MacDougall - Director, Investor Relations and Corporate Communications Andrew A

Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 15% and 117.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 15% and 117.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Conference call to occur at 4:30pm ET on August 4 Conference call to occur at 4:30pm ET on August 4